Medpace (NASDAQ:MEDP) Issues FY 2026 Earnings Guidance

Medpace (NASDAQ:MEDP) updated its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 17.250-17.950 for the period, compared to the consensus EPS estimate of 17.070. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion.

Medpace Trading Up 14.7%

Shares of NASDAQ:MEDP opened at $605.82 on Friday. The company has a market capitalization of $17.30 billion, a price-to-earnings ratio of 35.51, a PEG ratio of 2.64 and a beta of 1.15. Medpace has a 12-month low of $373.00 and a 12-month high of $677.90. The business has a 50-day moving average price of $488.37 and a 200 day moving average price of $493.74.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 109.14%. Medpace’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities research analysts predict that Medpace will post 17.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. BMO Capital Markets decreased their price objective on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a report on Friday, April 24th. Leerink Partners set a $620.00 target price on Medpace in a research report on Thursday. Robert W. Baird restated a “neutral” rating and set a $547.00 price target (up from $477.00) on shares of Medpace in a research note on Wednesday, July 8th. Royal Bank Of Canada decreased their price target on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $535.00 price target on shares of Medpace in a research report on Thursday. Two equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $502.00.

Insiders Place Their Bets

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. This represents a 44.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 20.50% of the stock is currently owned by insiders.

Trending Headlines about Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace reported second-quarter EPS of $4.25 and revenue of $707.3 million, both above expectations, showing that demand and execution remain strong. Medpace earnings report and conference call
• Positive Sentiment: The company raised fiscal 2026 guidance, signaling management has more confidence in its business momentum and future profitability. Medpace Soars After Q2 Beat, Strong Backlog Fuels Higher 2026 Outlook
• Positive Sentiment: Investors are also focusing on improving operating metrics, including a rebound in book-to-bill and a stronger backlog conversion rate, which suggest healthier future revenue visibility. Medpace: ‘Buy’ On Financial Metric Improvements And Solid Q2 2026 Earnings

Institutional Trading of Medpace

Hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC grew its stake in Medpace by 31.6% during the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after purchasing an additional 324,293 shares in the last quarter. Wasatch Advisors LP raised its position in Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after purchasing an additional 116,354 shares in the last quarter. Invesco Ltd. raised its position in Medpace by 18.9% in the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after purchasing an additional 85,517 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Medpace by 205.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after buying an additional 211,411 shares during the period. Finally, Bank of America Corp DE boosted its stake in shares of Medpace by 20.7% in the 3rd quarter. Bank of America Corp DE now owns 229,353 shares of the company’s stock valued at $117,924,000 after buying an additional 39,389 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.